RCn: a new class of micellar antitumor drugs with specific affinity for tumor cells membranes and ability to behave as nanocarriers for other bioactive molecules
- 詳細技術說明
- Recentgenerations of anti-cancer therapies provide more effective treatment withreduction of toxicity by two approaches: the use of a new drug with specifictumor-targeting properties, and the use of drug-loaded nanosized carriers. RCn moleculesrepresent a novel class of compounds that demonstrate effective anti-tumorproperties and limited toxicity as both a tumor-targeting drug and a micellecarrier.
- *Abstract
-
None
- *Inquiry
- Andrew CorrisThe Research Institute atNationwide Children's HospitalOffice of TechnologyCommercialization700 Children'sDrive Columbus OH 43205T: 614 355-1604 F: 614722-2716Andrew.Corris@nationwidechildrens.org
- *IP Issue Date
- None
- *IP Type
- Other Patent
- 國家
- Not Available
- 申請號碼
- None
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
